Caplacizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Caplacizumab
Monoclonal antibody
Type Single domain antibody
Source Humanized
Target VWF
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
Formula C1213H1891N357O380S10
Molar mass 27.88 kg/mol

Caplacizumab (INN) is a bivalent VHH designed for the treatment of thrombotic thrombocytopenic purpura and thrombosis.[1][2]

This drug is developed by Ablynx NV, and is currently in a phase III clinical trial.[3]

It is an anti-von Willebrand factor humanized immunoglobulin.[4] It acts by blocking platelet aggregation to reduce organ injury due to ischemia.[4] Results of the phase II TITAN trial have been reported.[4]

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Caplacizumab, American Medical Association.
  2. ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information. 25 (4). 
  3. ^ A Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura (HERCULES)
  4. ^ a b c Immune Drug Tackles Microvascular Thrombosis Disorder. Feb 2016